| Stage | GMED | % of rev | SYK | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $790M | 100.00% | $6.5B | 100.00% | SYK ×8.26 |
| Gross profit | $548M | 69.42% | $4.2B | 65.15% | GMED +4.3pp |
| Operating income | $182M | 23.10% | $1.0B | 15.86% | GMED +7.2pp |
| Pre-tax income | $190M | 24.04% | $997M | 15.29% | GMED +8.7pp |
| Net income | $152M | 19.20% | $753M | 11.55% | GMED +7.6pp |
| Stage | GMED | SYK | Gap · A − B |
|---|---|---|---|
| Revenue | $790M100.00% | $6.5B100.00% | SYK ×8.26 |
| Gross profit | 69.42%$548M | 65.15%$4.2B | GMED +4.3pp |
| Operating income | 23.10%$182M | 15.86%$1.0B | GMED +7.2pp |
| Pre-tax income | 24.04%$190M | 15.29%$997M | GMED +8.7pp |
| Net income |
| 19.20%$152M |
| 11.55%$753M |
| GMED +7.6pp |